

Contents

Preface	V
I. Cellular and subcellular mechanisms, energy turnover	
Introduction: Mechanisms of positive inotropic effects	
Scholz, H.	3
Adrenoceptors in myocardial regulation: concomitant contribution from both Alpha- and betaadrenoceptor stimulation to the inotropic response	
Osnes, J. B., H. Aass, T. Skomedal	9
Studies on the cellular mechanisms of action of positive and negative inotropic agents	
Watanabe, A. M., F. Green, Z. Ahmad	19
On the mechanism of positive inotropic effects of alpha-adrenoceptor agonists	
Schmitz, W., C. Kohl, J. Neumann, H. Scholz, J. Scholz	23
Cytosolic sodium concentration regulates contractility of cardiac muscle	
Sheu, S.-S.	35
Energy requirements of contraction and relaxation: implications for inotropic stimulation of the failing heart	
Katz, A. M.	47
Genetic and non-genetic control of myocardial calcium	
Alpert, N. R., E. M. Blanchard, L. A. Mulieri, R. Nagai, A. Zarain-Herberg, M. Periasamy	55
II. Pharmacology of positive inotropic substances	
Regulation of force and intracellular calcium transients by cyclic AMP generated by forskolin, MDL 17,043 and isoprenaline, and its modulation by muscarinic receptor agents: a novel mechanism for accentuated antagonism	
Endoh, M.	69
Studies on the mechanism of action of the bipyridine milrinone on the heart	
Farah, A. E., C. J. Frangakis	85
Ca-Agonists: a new class of inotropic drugs	
Bechem, M., R. Gross, S. Hebisch, M. Schramm	105
Myofibrillar Ca⁺⁺ activation and heart failure – Ca⁺⁺ sensitization by the cardiotonic agent APP 201–533	
Herzig, J. W., L. H. Botelho, R. J. Solaro	117

Positive inotropic stimulation in the normal and insufficient human myocardium

Erdmann, E., M. Böhm 125

Do human cardiac beta-2 adrenoceptors play a (patho)physiological role in regulation of heart rate and/or contractility?

Brodde, O.-E., H.-R. Zerkowski 135

III. Clinical experience with positive inotropic substances**Influence of isoproterenol on myocardial energetics. Experimental and clinical investigations**

Hasenfuss, G., C. Holubarsch, E. M. Blanchard, L. A. Mulieri, N. R. Alpert, Hj. Just 147

Effects of long-term xamoterol therapy on the left ventricular mechanical efficiency in patients with ischemic heart disease

Pouleur, H., C. van Eyll, J. Etienne, H. van Mechelen, A. Vuylsteke, M. F. Rousseau 157

Modulation of the autonomic control of the failing heart

Snow, H. M. 163

Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?

Meinertz, T., H. Drexler, Hj. Just 177

The use of levodopa, an oral dopamine precursor, in congestive heart failure

Broderick, G., S. I. Rajfer 187

Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure

Hasenfuss, G., Hj. Just 191

Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors

Schlepper, M., J. Thormann, V. Mitrovic 197

Phosphodiesterase inhibitors: alterations in systemic and coronary hemodynamics

Chatterjee, K. 213

Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside

Hasenfuss, G., C. Holubarsch, H. W. Heiss, B. Rattert, Hj. Just 225

IV. Energetic aspects in the intact heart**Myocardial energetics: experimental and clinical studies to address its determinants and aerobic limit**

Weber, K. T., J. S. Janicki, P. Sundram 237

Use of a conductance catheter to detect increased left ventricular inotropic state by end-systolic pressure-volume analysis

Leatherman, G. F., T. L. Shook, S. M. Leatherman, W. S. Colucci 247

Separation between vasodilation and positive inotropism by assessment of myocardial energetics in patients with dilated cardiomyopathy

Holubarsch, Ch., G. Hasenfuss, M. Allgeier, H. W. Heiss, Hj. Just 257

Subject index 267